Virologie最新文献

Fanleaf degeneration disease is referred to as "ortiage" in the French literature in 1723. Nowadays it occurs in most vineyards worldwide. Grapevine fanleaf virus (GFLV) is the main causal agent of the disease. It was identified in 1960 following the identification of the ectoparasitic dagger nematode Xiphinema index as its exclusive vector. The expression of the bipartite viral genome has been characterized and functions have been assigned to most viral proteins. Remarkably, the viral RNAs are monouridylated. The virion structure was determined by crystallography and transmission determinants were mapped on the coat protein. Further, viral determinants of symptoms in leaves and roots of plant hosts, three suppressors of RNA silencing, and metabolic pathways dysregulated upon infection were identified. Despite tremendous progress, management responses are limited. Future research will undoubtfully better elucidate the different steps of the infection cycle and provide opportunities to apply transformative GFLV management solutions in the vineyard.

The conference gathered experts from many fields working on various aspects of virus-virus interactions, ranging from mutualistic to parasitic, and harnessing different approaches to studying virus evolution (e.g., molecular biology, theory, mathematical modelling, genomics, phylogenetics, clinical studies, laboratory experiments). Altogether, this allowed the common theme of virus-virus interactions to be addressed from myriad perspectives, by researchers representing the breadth of career stages in academia, including graduate students, postdocs, beginning faculty and established experts. Moreover, some participants represented industry and government agency labs studying translational goals, creating a vibrant conference that spanned basic and applied research on virus-virus interactions, where virus evolution featured prominently.

The conference gathered experts from many fields working on various aspects of virus-virus interactions, ranging from mutualistic to parasitic, and harnessing different approaches to studying virus evolution (e.g., molecular biology, theory, mathematical modelling, genomics, phylogenetics, clinical studies, laboratory experiments). Altogether, this allowed the common theme of virus-virus interactions to be addressed from myriad perspectives, by researchers representing the breadth of career stages in academia, including graduate students, postdocs, beginning faculty and established experts. Moreover, some participants represented industry and government agency labs studying translational goals, creating a vibrant conference that spanned basic and applied research on virus-virus interactions, where virus evolution featured prominently.

From October 27-30 2024, the 16th International Oncolytic Virotherapy Conference (IOVC) was held in Rotterdam, the Netherlands, a city that mirrors the spirit of resilience, conviction, and innovation of researchers in the field of oncolytic viruses. Rotterdam, renowned for its post-war rebuilding with cutting-edge architecture designed for a bright future in mind, provided a fitting reflection that oncolytic virotherapy is at a turning point in its evolution. Hosted at the International Congress Center De Doelen, the event gathered clinicians, scientists, and biotech leaders to showcase the most up-to-date clinical applications, novel viral platforms, targeted mechanisms, and immune-modulating strategies that will push the boundaries of cancer immunotherapy into the next era. We present here an overview of this engaging meeting and offer our own perspectives on where to dream and continue to build.

From October 27-30 2024, the 16th International Oncolytic Virotherapy Conference (IOVC) was held in Rotterdam, the Netherlands, a city that mirrors the spirit of resilience, conviction, and innovation of researchers in the field of oncolytic viruses. Rotterdam, renowned for its post-war rebuilding with cutting-edge architecture designed for a bright future in mind, provided a fitting reflection that oncolytic virotherapy is at a turning point in its evolution. Hosted at the International Congress Center De Doelen, the event gathered clinicians, scientists, and biotech leaders to showcase the most up-to-date clinical applications, novel viral platforms, targeted mechanisms, and immune-modulating strategies that will push the boundaries of cancer immunotherapy into the next era. We present here an overview of this engaging meeting and offer our own perspectives on where to dream and continue to build.